The long term objective of this research is to understand the molecular basis controlling extracellular matrix assembly, leading to possibilities for intervention in those connective tissue diseases characterized by excessive matrix deposition. Fibrosis commonly occurs following inflammation, when connective tissue cells remain """"""""activated."""""""" Despite much research, the molecular basis for matrix assembly at the cell surface is still not well understood. Cell culture studies have shown a clear role for integrins in fibronectin fibrillogenesis, an early and important step in this process. In addition, there are poorly understood roles for heparin-binding domains of fibronectin, and an intact microfilament cytoskeleton. Novel data now indicates that a cell surface heparan sulfate proteoglycan, syndecan 2, may be pivotal in matrix assembly. Transfected cells expressing syndecan 2 that lacks the terminal 14 amino acids in the cytoplasmic domain could not establish a pericellular matrix, unlike those transfected with the full length core protein, or wild-type or similarly truncated syndecan 4. Synthetic peptides encompassing this region of syndecan 2 were phosphorylated in vitro by protein kinase C, whose activation is needed for matrix fibrillogenesis. Signaling through the cytoplasmic domain of syndecan 2, may, therefore, play a major role in matrix metabolism. To test this, the proposed studies will: 1) confirm that a similar disruption of matrix assembly occurs when human dermal fibroblasts are transfected with truncated syndecan 2, and that this correlates with the expression level of the transfect product. 2) determine, by immunofluorescence and immunoprecipitation pulse-chase experiments, whether this is due to failure to externalize and/or bind fibronectin at the cell surface, or due to rapid internalization and degradation. 3) determine, by phosphorylation assays in vitro, and in cells containing normal or mutated syndecan 2, whether phosphorylation of the cytoplasmic domain mediates the signaling mechanism controlling matrix assembly. 4) determine, by FACS analysis, immunofluorescence, and binding assays, if altered metabolism correlates with integrin expression, usage or affinity resulting from expression of truncated syndecan 2.

Project Start
1997-02-15
Project End
1997-12-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
20
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Wang, Hui; Rayburn, Elizabeth R; Wang, Wei et al. (2006) Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 5:2106-14
Annis, D S; Murphy-Ullrich, J E; Mosher, D F (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459-68

Showing the most recent 10 out of 145 publications